Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.6K
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

1.0K
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
1.0K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

507
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
507
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

907
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
907
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

574
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
574

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring racial-specific associations between the food inflammation index(FII) and metabolic dysfunction-associated fatty liver disease (MAFLD) Prevalence: Data from the National Health and Nutrition Examination Survey 1999-2020.

Medicine·2026
Same author

A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis.

Science (New York, N.Y.)·2025
Same author

Nucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial.

Trials·2024
Same author

Mesenchymal Stem Cells Alleviate Acute Liver Failure through Regulating Hepatocyte Apoptosis and Macrophage Polarization.

Journal of clinical and translational hepatology·2024
Same author

Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence-Based Review on Emerging Clinical Data.

Clinical pharmacology and therapeutics·2024
Same author

Quantitative Measurement of Serum HBcrAg Can Be Used to Assess the Feasibility of Safe Discontinuation of Antiviral Therapy for Chronic Hepatitis B.

Viruses·2024

Related Experiment Video

Updated: Feb 6, 2026

Efficient Differentiation of Human Pluripotent Stem Cells into Liver Cells
07:37

Efficient Differentiation of Human Pluripotent Stem Cells into Liver Cells

Published on: June 11, 2019

9.2K

Progress in mesenchymal stem cell-based therapy for acute liver failure.

Yong-Hong Wang1, Dong-Bo Wu1, Bing Chen1

  • 1Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.

Stem Cell Research & Therapy
|August 26, 2018
PubMed
Summary

Mesenchymal stem cells show promise for treating acute liver failure, offering a potential alternative to liver transplantation. Research is exploring their therapeutic mechanisms and transplantation methods for this critical condition.

Keywords:
Acute liver failureMesenchymal stem cellsTreatment

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.0K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

Related Experiment Videos

Last Updated: Feb 6, 2026

Efficient Differentiation of Human Pluripotent Stem Cells into Liver Cells
07:37

Efficient Differentiation of Human Pluripotent Stem Cells into Liver Cells

Published on: June 11, 2019

9.2K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

11.0K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

Area of Science:

  • Regenerative Medicine
  • Hepatology
  • Stem Cell Biology

Background:

  • Acute liver failure (ALF) is a severe condition with high mortality, often requiring liver transplantation.
  • Current treatments for ALF primarily manage complications rather than cure the disease.
  • Liver transplantation, while curative, faces significant limitations in its application.

Purpose of the Study:

  • To review the therapeutic mechanisms of mesenchymal stem cells (MSCs) in ALF.
  • To discuss recent preclinical and clinical advancements in MSC-based ALF treatment.
  • To summarize methodological improvements in MSC transplantation for liver failure.

Main Methods:

  • Review of current scientific literature on MSCs and ALF.
  • Analysis of preclinical studies investigating MSC efficacy and mechanisms.
  • Evaluation of clinical trial data and transplantation techniques for MSCs in liver disease.

Main Results:

  • MSCs demonstrate significant therapeutic potential in treating ALF.
  • Key mechanisms include immunomodulation, anti-apoptosis, and promotion of liver regeneration.
  • Advancements in MSC sourcing, expansion, and delivery methods are improving treatment outcomes.

Conclusions:

  • Mesenchymal stem cells represent a promising therapeutic strategy for acute liver failure.
  • Further research and clinical trials are warranted to optimize MSC transplantation protocols.
  • MSC therapy may offer a viable alternative or adjunct to liver transplantation for ALF patients.